The momentum behind GLP-1 receptor agonists has become impossible to ignore. Originally developed to control blood glucose in diabetes, these therapies have surged to the forefront of obesity care, ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

A large study led by researchers at Case Western Reserve University suggests that semaglutide—a drug already popular for ...

So-called ‘skinny jabs’ are being prescribed to people who don’t need them, with terrifying side effects. How did our ...

Novo Nordisk (NYSE: NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

A new study suggests that popular weight loss medications could significantly benefit patients awaiting kidney transplants.